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Conclusions: We showed that CRP levels are associated with OA-
related knee pain in women. This might indicate that there is an in-
ﬂammatory component present in knee OA that contributes to knee pain
experienced in OA. In addition, we showed that BMI modiﬁes the effect
of CRP levels on KOA. This may indicate a difference in pathogenesis of
OA in overweight women compared to women with a healthy weight. For
example, mechanical load is a major contributor in overweight women,
whilst in women with a healthy weight systemic inﬂammation might play
a more prominent role.
Another explanation could be that we do not see the effect in overweight
women because of confounding by co-morbidity such as cardiovascular
disease or diabetes, although we tried to adjust for this in our analysis.
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Purpose: In OA trials, rates of placebo response are often 50%+. Despite
this, little is known about sociodemographic or clinical predictors. We
hypothesized that rates of response and predictors would be similar
between patients in North America (NA) vs. Europe (EUR).
Methods: Data were drawn from 622 males and females randomized
to the placebo arm of a large multinational clinical trial designed to
evaluate the clinical effects of a bisphosphonate on knee OA. Patients
were 40−80 years of age who reported knee pain due to OA on most
days during 1 of the prior 3 months, morning stiffness lasting <30min or
knee crepitus according to the ACR criteria for knee OA. No minimum
level of pain was required. Patients also had 1+ osteophytes, joint space
width (JSW) of 2−4mm in the medial tibiofemoral compartment, and a
medial compartment < lateral. WOMAC pain and function scales were
administered at baseline and 6 months. OARSI 2004 Responder Criteria
were used to classify participants at 6 months.
Results: 552 (83%) patients completed the 6 month evaluations. Overall,
patients were mostly female (63%) and white (79.2%) with a mean (±SD)
age of 62.0±8.8 years, BMI of 29.8±4.6, and JSW of 3.0±0.6mm. EUR
patients were signiﬁcantly (p< 0.01) older, more likely to be female, lighter
and use less analgesic medication. EUR patients also had signiﬁcantly
(p< 0.01) higher WOMAC pain, function and patient global assessment
scores at baseline.
More participants in the EUR as compared to the NA sites met the
criteria for treatment response (23.5% vs. 21.0%, respectively), although
the difference was not statistically signiﬁcant (p = 0.488). A breakdown of
patients meeting criteria for high response and improvement by cohort is
shown below.
At baseline, placebo responders had signiﬁcantly lower scores for
WOMAC pain (31.6±1.5 vs. 41.6±1.1; p< 0.001), function (37.8±1.7
vs. 44.9±1.2; p< 0.001) and patient global assessment (50.2±2.2 vs.
55.4±1.1; p = 0.032). No statistically signiﬁcant differences were found
between responders and non-responders for age, gender, body mass
index, baseline JSW, OARS grade, osteophytes or use of pain medica-
tion. In multivariate logistic regression models, even with adjustment for
baseline sociodemographic and OA-related characteristics, baseline pain
was the only consistent predictor of placebo response in both joint and
separate models.
Conclusions: Using OARSI Response Criteria, more than 1 in 5 partic-
ipants who were in the placebo arm met stringent criteria for treatment
response. Responders were more likely to report moderate levels of pain
and impairments in physical function than non-responders at baseline.
Overall, there do not appear to be sociodemographic or OA-related
characteristics reliably associated with placebo response.
Pain: Pathophysiology
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Purpose: To assess skin sensitisation over the medial aspect of the knee
in people with osteoarthritis (OA) of the knee, using quantitative sensory
testing (QST) and relate this to their pain experiences
Methods: 28 patients with established medial compartment tibiofemoral
joint OA were recruited to the study. They were interviewed about pain,
and they completed WOMAC, HADs and MGill pain questionnaires. QST
was then used to assess any area of altered sensation in the skin, test
for mechanical sensitivity and pain thresholds, and assess skin thermal
sensitivity.
Results: The group included 20 women and 8 men with a mean age of
62.8 years, knee pain of an averge of 5 years duration, and radiographic
evidence of medial compartment knee OA. Their mean WOMAC and
HADs scores were 47.8 (range 16−73) and 14.2 (6−31) respectively.
26/28 had an area of altered sensation over the medial aspect of the index
knee. Sensitivity to touch was lower in that knee, but pain threshold higher
than in the contralateral knee. 19/28 had thermal allodynia, severe in 4.
Those with cold allodynia had higher WOMAC and HADs scores than
the whole group, and were more likely to use McGill pain descriptors
suggesting of neuropathic pain.
Conclusions: Sensory processing is altered in most patients with knee
OA, and in some cases neuropathic pain may make an important contri-
bution to the pain experience. This has implications for therapy.
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STUDY
K. Baker1, A. Grainger2, J. Niu1, M. Clancy1, A. Guermazi1, M. Crema1,
L. Hughes3, J. Buckwalter4, M. Nevitt5, D. Felson1. 1BUMC, Boston,
MA, USA, 2U Leeds, Leeds, UNITED KINGDOM, 3UAB, Birmingham,
AL, USA, 4U Iowa, Iowa City, IA, USA, 5UCSF, San Francisco, CA, USA
Purpose: Pain from knee OA is a key symptom in the decision to seek
medical care and an important antecedent to disability. Synovitis has
been hypothesized as one pathological feature that causes pain. Synovial
thickening on contrast enhanced (CE) MRI has been shown to correlate
well with synovitis on histology. On non CE MRIs synovial thickening
cannot be assessed and on these images synovitis has been weakly
and inconsistently associated with pain. We used CE MRIs, to assess
synovial thickening in relation to knee pain severity among subjects in
the Multicenter Osteoarthritis Study (MOST).
Methods: MOST is a NIH-funded longitudinal observational study of risk
factors for knee structural changes and occurrence of pain in persons age
50−79 with or at high risk of knee OA. An unselected subset of partici-
pants who volunteered obtained 1.5 CE MRI of one knee at the 30 month
clinic visit. Synovitis was scored 0−3 in 4 compartments (suprapatellar
pouch, medial and lateral parapatellar recesses and infrapatellar fat
pad) and 0−1 in 2 compartments (medial and lateral posterior condylar)
(Rheumatol 44:1569 2005). We categorized synovitis in the whole knee
as severe (>1 compartment scored 3), moderate (>2 compartments
scored 2 but no 3s), mild (>4 compartments scored 1 or 1 scored 2),
normal/questionable (<4 compartments scored as 1). Inter-reader kappa
was 0.9 (p< 0.001). Subjects were asked about their knee pain severity
using WOMAC. Each of the 5 items in the WOMAC pain scale is scored
from 0 (no pain) to 4 (extreme pain). We used the maximum item score
to deﬁne the categories of knee pain severity: no-pain (all 5 items scored
0 prior to a clinic visit), mild-pain (maximum score of any item 3). We
examined the association between synovitis and pain severity using a
logistic regression model adjusting for age, sex, BMI, MRI bone marrow
edema, and effusions. We also examined if the effect of synovitis on pain
severity was modiﬁed by radiographic OA status.
Table 1
All subjects Synovitis
Worst pain on any WOMAC
pain question
Normal/
questionable
(n = 151)
Mild (n = 233) Moderate/severe
(n = 69)
None (n = 158) 69 (46%) 79 (34%) 10 (15%)
Mild (n = 149) 45 (29%) 79 (34%) 25 (36%)
Moderate/severe/extreme
(n = 146)
37 (25%) 75 (32%) 34 (49%)
Adj OR for mild pain vs no
pain (95%CI)*
1.0 1.4 (0.9, 2.4) 3.1 (1.2, 8.0) p for trend 0.02
Adj OR for moderate/
severe/extreme pain vs no
pain (95%CI)*
1.0 1.9 (1.0, 3.3) 4.8 (1.8, 12.3) p for trend 0.001
Subjects KL< 2, no PF OA n=132 n=149 n=16
None 62 (47%) 61 (41%) 5 (31%)
Mild/moderate/severe/extreme 70 (53%) 88 (59%) 11 (69%)
Adj OR for pain (95%CI)* 1.0 1.4 (0.8, 2.3) 2.2 (0.6, 8.1) p for trend 0.15
*Adjusted for age, sex, BMI and MRI bone marrow edema and effusions
